Compare ARK Genomic Revolution ETF (ARKG) vs New York Times Co (NYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs New York Times Co — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while New York Times Co trades at $75 (market cap $12.13B). The key difference: New York Times Co pays a 1.23% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, New York Times Co nearer its low. Which is the better fit depends on your goals.
| ARKG | NYT | |
|---|---|---|
Sector | Sector/Thematic | Media |
52-Week High | $43.57 | $85.86 |
52-Week Low | $23.09 | $51.43 |
Market Cap | — | $12.13B |
Enterprise Value | — | $11.53B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
The New York Times (NYT) stock trades at $74.96, up 0.89% on the day, reflecting steady growth. Recent earnings have consistently beaten estimates, with Q1 2026 EPS of $0.61 surpassing the $0.47 expectation. Revenue reached $2.82B in 2025, with net income margin improving to 12.17%. Technical indicators show a bullish trend, while analyst consensus is a $78 price target. Recent news highlights legal actions involving OpenAI and government subpoenas, adding to operational scrutiny.
Outlook remains positive due to strong earnings performance and revenue growth, but risks include legal battles and regulatory pressures. The stock offers potential upside to the consensus target, supported by solid cash flow and profitability metrics. Investors should weigh these factors against ongoing litigation and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →
